The Impacts on the BioPharma Industry from Recent and Potential Changes in Healthcare Policy: A Conversation with Neal Masia, Healthcare Policy Consultant and CEO of Healthcare Capital Group

In this episode of “Journey Through the Growth Economy,” CG’s Biotechnology team of analysts including Whitney Ijem, Sumant Kulkarni, John Newman, Ph.D., CFA, and Edward Nash host Neal Masia, a healthcare policy consultant and advisor to discuss the latest updates on healthcare policy and regulators and the impacts on the biotechnology industry. For further detail on Masia, he is the CEO of Healthcare Capital Group and serves as a research analyst and strategist to help a variety of healthcare companies and healthcare-focused investment firms navigate the changing environment. Masia helps answer questions that are top of mind for investors when it comes to impacts on the biotechnology space from recent policy such as the One Big Beautiful Bill Act and changes in members of key healthcare agencies. He speaks to the likelihood of the administration fulfilling the “Most Favored Nation”  drug pricing policy which aims to dramatically lower drug prescription costs in the United States. 

--

Please visit https://www.canaccordgenuity.com/capital-markets/expertise/research-and-strategy/ for more details on Canaccord Genuity Research and send all inquiries to strategicinsights@cgf.com.
 
This content is for informational purposes only and should not be taken as legal, business, financial or investment advice. This content is not intended to promote any product or service of Canaccord Genuity.

The opinions and views expressed in this program may not necessarily reflect the institutional views of Canaccord Genuity or its affiliates. 

This program should not be copied, distributed, published, or reproduced in whole or in part without the expressed written consent of Canaccord Genuity. 

Certain information contained in this program constitutes forward looking statements and there is no guarantee that these results will be achieved. Canaccord Genuity has no obligation to provide updates or changes to the information in this program. Past performance does not guarantee future results which may vary. 

Canaccord Genuity LLC is a registered broker-dealer regulated by the SEC and FINRA. Member SIPC. Canaccord Genuity Corp. Member CIRO/Canadian Investor Protection Fund. Canaccord Genuity Limited, Authorized and Regulated by the Financial Conduct Authority, Member LSE. Offices in other countries are offices of other companies in the Canaccord Genuity group of companies.
 
Canaccord Genuity Research Disclosures are available at the following link: https://canaccordgenuity.bluematrix.com/sellside/Disclosures.action